Achilles Therapeutics plc (ACHL)
NASDAQ: ACHL · IEX Real-Time Price · USD
0.774
-0.015 (-1.91%)
At close: Apr 25, 2024, 3:59 PM
0.765
-0.009 (-1.21%)
After-hours: Apr 25, 2024, 7:27 PM EDT

Achilles Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year Current20232022202120202019
Market Capitalization
323637203--
Market Cap Growth
--1.60%-81.89%---
Enterprise Value
-95-91-128-51-162-97
PE Ratio
-0.52-0.52-0.52-3.33--
PB Ratio
0.220.260.190.70--
P/FCF Ratio
-0.73-0.73-0.55-3.04--
P/OCF Ratio
-0.75-0.75-0.62-3.43--
EV/EBITDA Ratio
1.411.411.900.884.997.09
EV/EBIT Ratio
1.311.311.800.834.886.94
EV/FCF Ratio
1.831.831.910.764.366.44
Debt / Equity Ratio
0.030.030.040.040.080.00
Debt / EBITDA Ratio
-0.07-0.07-0.13-0.21-0.49-0.04
Debt / FCF Ratio
-0.09-0.09-0.13-0.18-0.43-0.03
Quick Ratio
7.747.749.6313.9410.7025.30
Current Ratio
8.578.5710.9314.9011.3026.72
Return on Equity (ROE)
-42.60%-42.60%-31.70%-22.30%-22.80%-
Return on Assets (ROA)
-37.50%-37.50%-28.50%-20.30%-20.50%-
Return on Capital (ROIC)
-51.20%-51.20%-38.12%-21.27%-16.42%-13.53%
Earnings Yield
-218.97%-192.15%-193.18%-30.04%--
FCF Yield
-155.74%-136.66%-181.97%-32.90%--
Buyback Yield / Dilution
-2.13%-2.13%-36.59%-2587.54%-66.03%-
Total Shareholder Return
-2.13%-2.13%-36.59%-2587.54%-66.03%-
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).